Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Stock Price Today
Aura AI Summary
Key Stats
- $394.18MMarket Cap
- 84,843Volume
- Income / Options OverlaySector
- $107.4152W High
- $61.8152W Low
- 63 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 has traded between a low of $61.81 and a high of $107.41, highlighting its annual price range. Buy and sell Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.